Geller Chloé, Fontanay Stéphane, Finance Chantal, Duval Raphaël E
SRSMC, Nancy-University, CNRS, Nancy, France.
J Virol Methods. 2009 Aug;159(2):217-26. doi: 10.1016/j.jviromet.2009.03.023. Epub 2009 Apr 5.
The relative lack of efficient methods for evaluating antiseptic antiviral activity, together with weaknesses in the existing European Standard (i.e. NF EN 14476+A1), underlines the need to seek a new method which could allow a more precise evaluation of the antiseptic antiviral activity of chemical agents. This protocol is based on an original gel-based filtration method, using "in-house" G-25 and G-10 Sephadex columns. This method allows the neutralization of both the activity and the cytotoxicity of a large range of molecules, according to their molecular size, in only 1min. The viral model used was the human coronavirus (HCoV) 229E chosen for (i) its increasing medical interest, (ii) its potential resistance and (iii) its representing enveloped viruses mentioned in the European Standard. First, the protocol was validated and it was demonstrated that it was fully operational for evaluating antiviral antiseptic potentiality and useful to screen potentially antiseptic molecules. Second, chlorhexidine (CHX) and hexamidine (HXM) were assessed for their potential anti-HCoV 229E antiseptic activities. It was demonstrated clearly that (i) HXM had no activity on the HCoV 229E and (ii) CHX showed a moderate anti-HCoV 229E activity but insufficient to be antiseptic.
评估抗菌抗病毒活性的有效方法相对匮乏,再加上现有欧洲标准(即NF EN 14476+A1)存在缺陷,凸显了寻求一种新方法的必要性,该方法能够更精确地评估化学药剂的抗菌抗病毒活性。本方案基于一种原始的凝胶过滤方法,使用“自制”的G-25和G-10葡聚糖凝胶柱。这种方法能够根据分子大小,在仅1分钟内中和多种分子的活性和细胞毒性。所使用的病毒模型为人冠状病毒(HCoV)229E,选择它是因为(i)其在医学上的关注度不断提高,(ii)其潜在抗性,以及(iii)它代表了欧洲标准中提到的包膜病毒。首先,对该方案进行了验证,结果表明它在评估抗病毒抗菌潜力方面完全可行,并且有助于筛选潜在的抗菌分子。其次,评估了洗必泰(CHX)和己脒定(HXM)对HCoV 229E的潜在抗菌活性。结果清楚地表明,(i)HXM对HCoV 229E没有活性,(ii)CHX表现出中等程度的抗HCoV 229E活性,但不足以作为抗菌剂。